Eli Lilly and Company (LLY) To Go Ex-Dividend on November 13th

Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend on Monday, October 26th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share on Thursday, December 10th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th.

Eli Lilly and Company has raised its dividend by an average of 0.2% annually over the last three years and has raised its dividend every year for the last 11 years. Eli Lilly and Company has a payout ratio of 23.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Eli Lilly and Company to earn $50.07 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 13.8%.

Eli Lilly and Company Trading Up 1.5%

LLY opened at $1,432.60 on Wednesday. The stock has a market capitalization of $1.35 trillion, a price-to-earnings ratio of 46.50, a P/E/G ratio of 1.69 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00. The company has a 50-day simple moving average of $1,225.57 and a 200 day simple moving average of $1,104.56.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same period last year, the firm earned $7.02 EPS. The business’s quarterly revenue was up 38.6% compared to the same quarter last year. Analysts predict that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This represents a 54.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.

Institutional Trading of Eli Lilly and Company

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE acquired a new position in shares of Eli Lilly and Company during the second quarter worth $13,522,666,000. Jupiter Topco LLC acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $4,667,180,000. Corient Private Wealth LP acquired a new stake in Eli Lilly and Company in the second quarter worth $764,116,000. BlackRock Inc. grew its stake in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the period. Finally, State Street Corp grew its stake in Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after acquiring an additional 605,752 shares during the period. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.